Oral Hereditary Angioedema Therapy Matches Clinical Performance of Standard Injectables
Late-breaking Phase 3 trial data shows that the once-daily oral medication deucrictibant reduced monthly swelling attacks by 83 percent. The investigational drug offers prophylactic efficacy comparable to current biologic injections, potentially transforming how the rare genetic condition is managed.
Share this story
Patients managing hereditary angioedema may soon have a once-daily oral medication that prevents severe swelling attacks as effectively as current injectable therapies. Late-breaking clinical data presented at the American College of Allergy, Asthma and Immunology 2026 Annual Scientific Meeting showed that the investigational drug deucrictibant reduced monthly attack rates by 83 percent compared to a placebo. The results position the therapy as a potential turning point in managing the rare genetic condition.[2][3][4]
The Phase 3 trial, known as CHAPTER-3, evaluated an extended-release formulation of the drug in 85 adolescents and adults across 21 countries. Participants were randomized to receive either 40 milligrams of deucrictibant or a placebo every day for 24 weeks. The study enrolled individuals with all three major types of the disease, making it the first late-stage prophylaxis trial to include such a broad patient population.[3][4][5]
"We have some treatment options currently, and I think, if approved, this would add a really valuable tool to the toolbox," said Marc A. Riedl, clinical director of the U.S. Hereditary Angioedema Association Angioedema Center at the University of California, San Diego. Riedl presented the findings in Phoenix, noting that the oral therapy provided injectable-like efficacy. The protection began within the first week of treatment and remained consistent throughout the study period.[2]
Among the 80 participants diagnosed specifically with Type 1 or Type 2 hereditary angioedema, the reduction in monthly attacks reached 87 percent. Nearly half of the patients receiving the active drug—45 percent—remained completely attack-free for the entire 24 weeks. Furthermore, 98 percent of treated individuals achieved at least a 50 percent reduction in their attack frequency relative to their baseline.[2][4]
Redefining Prophylactic Control
The trial also tracked the severity of the breakthrough episodes that did occur. The rate of attacks requiring on-demand rescue medication fell by 83 percent, while the frequency of moderate-to-severe attacks dropped by 77 percent. These metrics are critical for patients, as severe episodes can involve the gastrointestinal tract or airways, leading to hospitalization or fatal asphyxiation.[3][4]
Long-term safety and durability data presented alongside the Phase 3 results further supported the drug's profile. Final results from an open-label extension of an earlier Phase 2 study showed that participants maintained a 92.4 percent average reduction in attack rates over nearly 34 months of continuous treatment. The mean monthly attack rate in that cohort dropped from 2.18 at baseline to just 0.12 during the extension phase.[3]
Cardiovascular safety has been a particular focus during the clinical development program. An integrated safety assessment covering more than 740 participants across 25 studies found no evidence that the drug prolongs the QTc interval or increases cardiovascular risk. In the CHAPTER-3 trial specifically, researchers reported no treatment-related serious adverse events and no clinically significant abnormalities in heart rate or blood pressure.[4]
Quality of life metrics mirrored the clinical outcomes. Patients taking the extended-release tablets reported significantly larger improvements in their Angioedema Quality of Life total scores compared to the placebo group. The most pronounced gains were observed in the functioning and fear domains, reflecting the psychological relief of gaining reliable control over unpredictable swelling episodes.[2]
Rapid Relief for Breakthrough Attacks
While the extended-release tablet is designed for daily prevention, Pharvaris is simultaneously developing an immediate-release capsule for on-demand treatment. Separate Phase 3 data from the RAPIDe-3 trial demonstrated that the 20-milligram immediate-release formulation rapidly halted the progression of acute attacks. The median time to the end of symptom progression was just 17.47 minutes for patients taking the drug, compared to more than three and a half hours for those on placebo.[4]
More than 95 percent of the attacks treated with the immediate-release capsule maintained symptom relief and resolution without requiring additional intervention. Over 80 percent of those episodes were successfully managed with a single dose. This rapid onset of action is crucial during acute flares, where immediate intervention can prevent a minor swelling event from escalating into a medical emergency.[3]
Pharmacokinetic modeling presented at the conference suggests that the two formulations can be safely used together. This dual approach would allow a patient to take the extended-release tablet daily for baseline protection, while keeping the immediate-release capsules on hand to manage any breakthrough attacks. If approved, deucrictibant could become the first oral therapy to span both prophylactic and on-demand indications.[3][4]
Pharvaris intends to redefine disease management by uniting on-demand treatment and long-term prophylaxis within a single therapeutic franchise, according to the company's clinical updates. The strategy aims to simplify care for patients who currently rely on a patchwork of different medications, often mixing oral prophylactic drugs with injectable rescue therapies.[3][4]
The Mechanism Behind the Molecule
Hereditary angioedema is driven by the overproduction of bradykinin, a peptide that promotes inflammation and causes blood vessels to dilate and leak fluid into surrounding tissues. Deucrictibant works as a bradykinin B2 receptor antagonist. By blocking the specific receptor that bradykinin binds to, the drug prevents the peptide from triggering the vascular permeability that leads to swelling.[2]
This mechanism of action distinguishes deucrictibant from other available therapies that target upstream enzymes like plasma kallikrein or C1 esterase inhibitor. Because it acts directly at the downstream receptor, the drug is effective regardless of which specific biochemical pathway generated the excess bradykinin. This broad applicability explains its efficacy across all three major subtypes of the disease.[2]
The inclusion of patients with normal C1 inhibitor levels in the CHAPTER-3 trial is particularly notable. This subgroup is often excluded from clinical trials and the prescribing labels of approved prophylactic agents, leaving them with fewer evidence-based treatment options. Demonstrating efficacy in this population broadens the potential clinical utility of the new therapy.[2][4]
The extended-release formulation achieves its once-daily dosing profile by controlling the absorption of the active ingredient through the small intestine and colon. Phase 1 pharmacokinetic studies showed that a 40-milligram tablet sustains therapeutic concentrations in the bloodstream for a full 24 hours, eliminating the need for the twice-daily dosing required by the immediate-release capsules.[3]
Economic Burden and Market Landscape
The clinical advances come against the backdrop of a substantial economic burden associated with the disease. A United States claims analysis presented at the meeting evaluated 952 adolescents and adults with hereditary angioedema over a median of 2.4 years. The review found that 20.3 percent of the patients required at least one hospital stay related to their condition, and 25.4 percent visited an emergency room.[3]
The financial toll of managing the condition is immense. The claims analysis revealed that the median medical and pharmacy costs per patient reached $240,064 annually during the follow-up period, up from $43,271 at baseline. The high costs are largely driven by the expense of existing biologic therapies and the emergency care required when breakthrough attacks occur.[3]
The prophylactic market for hereditary angioedema is highly competitive, currently dominated by injectable biologic drugs and existing oral therapies. While current oral options offer the convenience of a once-daily pill, the 83 percent attack reduction observed with deucrictibant in the CHAPTER-3 trial positions it as a potentially more potent alternative that mirrors the efficacy of injectables.[2][3]
If the Phase 3 results translate into real-world effectiveness, deucrictibant could challenge both existing oral options and standard injectable therapies. Patients generally prefer oral medications over subcutaneous injections or intravenous infusions, provided they do not have to sacrifice clinical efficacy to gain that convenience.[2][3]
Next Steps for Regulatory Approval
Pharvaris has already submitted a New Drug Application to the United States Food and Drug Administration for the immediate-release capsule as an on-demand treatment. The agency accepted the filing with a target action date of April 23, 2027. A parallel marketing authorization application is currently under review by the European Medicines Agency.[3]
Pharvaris has already submitted a New Drug Application to the United States Food and Drug Administration for the immediate-release capsule as an on-demand treatment.
For the extended-release prophylactic tablet, the company plans to submit marketing applications in the first half of 2027, using the CHAPTER-3 data as the foundation for its filing. The regulatory timeline suggests that the on-demand formulation could reach the market first, followed closely by the prophylactic tablet if the agencies grant approval.[3][4]
Until the regulatory reviews are complete, deucrictibant remains an investigational drug. However, an expanded access program is currently available in the United States for eligible patients seeking the immediate-release formulation for on-demand treatment. The coming year will determine whether the dual-formulation strategy successfully transitions from clinical trials to standard clinical practice.[3]
Key points
- Once-daily oral deucrictibant extended-release reduced monthly hereditary angioedema attacks by 83 percent in a Phase 3 trial.
- The therapy demonstrated efficacy across all three major subtypes of the disease, with 45 percent of patients remaining completely attack-free for 24 weeks.
- A separate immediate-release formulation halted the progression of acute breakthrough attacks in a median time of 17.47 minutes.
- The manufacturer plans to submit regulatory applications for the prophylactic tablet in the first half of 2027, aiming to offer a unified oral treatment strategy.
Unanswered questions
- How the real-world adherence to a daily oral prophylactic will compare to the adherence rates of monthly or bi-weekly injectables.
- Whether the long-term cardiovascular safety profile will remain pristine once the drug is used by a broader, more diverse patient population over several years.
- The exact pricing strategy Pharvaris will adopt if both the extended-release and immediate-release formulations are approved.
How we got here
July 2026
The FDA accepted the New Drug Application for the immediate-release formulation of deucrictibant for on-demand treatment.
September 2026
Pharvaris announced topline results from the Phase 3 CHAPTER-3 trial demonstrating an 83 percent reduction in attack rates.
November 2026
Detailed clinical and quality-of-life data were presented at the ACAAI Annual Scientific Meeting in Phoenix.
April 2027
The FDA's target action date for the on-demand immediate-release capsule.
First Half 2027
Planned submission of marketing authorization applications for the extended-release prophylactic tablet.
- Clinical Investigators
- Medical professionals emphasize the therapy's potential to replace burdensome injections without sacrificing efficacy.
- Drug Developers
- The manufacturer focuses on the dual-formulation strategy to address unmet needs across all disease subtypes.
- Health Economists
- Analysts focus on the potential for effective oral prophylaxis to reduce the staggering costs of emergency interventions.
Perspectives this story doesn't cover
- Patients currently managing hereditary angioedema with standard injectable therapies
- Insurance providers evaluating the cost-effectiveness of a new branded oral prophylactic
Sources
[1]MedPage TodayClinical InvestigatorsNovel Oral HAE Drug Measures Up to Injectable Options
Read on MedPage Today →
[2]HealioClinical InvestigatorsLarge reduction in hereditary angioedema attack rate found with deucrictibant tablets
Read on Healio →
[3]BioSpaceDrug DevelopersPharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Read on BioSpace →
[4]MedPathDrug DevelopersPharvaris Reports Positive Phase 3 CHAPTER-3 Results for Deucrictibant XR in Hereditary Angioedema
Read on MedPath →
[5]ClinicalTrials.govStudy to Evaluate the Efficacy and Safety of Deucrictibant XR Tablet for Prophylaxis of Attacks in Adolescents and Adults With Hereditary Angioedema (CHAPTER-3)
Read on ClinicalTrials.gov →
More in Health
See all →Gaucher Disease
FDA Approves Venglustat as First Treatment for Neurological Symptoms of Type 3 Gaucher Disease
6 sources
Breast Cancer Treatment
FDA Approves Roche's Oral Therapy Giredestrant for Advanced Breast Cancer
4 sources
Kidney Disease
US Regulators Approve First Targeted Treatment for Primary Membranous Nephropathy
7 sources
Obesity Treatments
China Approves Eli Lilly's Orforglipron as First Oral GLP-1 Weight-Loss Pill
5 sources
Comments
Every angle. Every day.
Get Health stories with full source coverage and perspective breakdowns, free every day.




